Equities

Repligen Corp

Repligen Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)146.07
  • Today's Change3.49 / 2.45%
  • Shares traded578.06k
  • 1 Year change-9.71%
  • Beta0.9514
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Repligen Corp's revenues fell -20.31% from 801.54m to 638.76m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 185.96m to 41.58m, a -77.64% decrease.
Gross margin50.37%
Net profit margin-2.75%
Operating margin-1.92%
Return on assets-0.64%
Return on equity-0.86%
Return on investment-0.70%
More ▼

Cash flow in USDView more

In 2023, Repligen Corp increased its cash reserves by 43.53%, or 227.87m. Cash Flow from Financing totalled 248.96m or 38.98% of revenues. In addition the company generated 113.92m in cash from operations while cash used for investing totalled 123.28m.
Cash flow per share0.9142
Price/Cash flow per share155.61
Book value per share36.00
Tangible book value per share11.57
More ▼

Balance sheet in USDView more

Repligen Corp has a Debt to Total Capital ratio of 20.55%.
Current ratio10.44
Quick ratio8.76
Total debt/total equity0.2587
Total debt/total capital0.2055
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -77.26%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)15.08
EPS (TTM) vs
TTM 1 year ago
-117.41
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.